Search

Your search keyword '"Spencer, Lisa"' showing total 466 results

Search Constraints

Start Over You searched for: Author "Spencer, Lisa" Remove constraint Author: "Spencer, Lisa"
466 results on '"Spencer, Lisa"'

Search Results

2. Advances and ongoing challenges in eosinophilic gastrointestinal disorders presented at the CEGIR/TIGERs Symposium at the 2024 American Academy of Allergy, Asthma & Immunology meeting

3. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK

5. Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease

8. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

9. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

11. Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review.

12. New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting.

13. New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting

16. Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease.

18. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

19. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

20. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

21. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

22. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH):a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial

23. Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis

25. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK

26. A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis

27. Residual Lung Abnormality Following COVID-19 Hospitalisation is Characterised by Epithelial Injury

28. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK

29. Notch 2 signaling contributes to intestinal eosinophil adaptations in steady state and tissue burden following oral allergen challenge.

30. Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.

33. Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis

34. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial

37. Late Breaking Abstract - Morphine sulfate for the treatment of cough in Idiopathic Pulmonary Fibrosis The PAciFy Cough Randomized Clinical Trial

39. Real-world data from 24 UK centres for the use of nintedanib for progressive fibrosing interstitial lung disease

41. Genetic and geographic influence on phenotypic variation in European sarcoidosis patients

44. Residual Lung Abnormalities after COVID-19 Hospitalization: Interim Analysis of the UKILD Post–COVID-19 Study

45. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

46. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

47. A Professional Learning Program Designed to Increase K-12 Teachers' Instructional Technology Use

48. Using Diffusion of Innovation Theory to Address Health of the Homeless in Hawaii.

Catalog

Books, media, physical & digital resources